In the race to transform customer value through technology, the healthcare sector has always been an important factor. Precision medicine could change the game. Your visionaries hope that it will bring us ever closer to a world where you can take a pill for all your personalized medicines and control them with your smartphone; where an app that integrates everything from your molecular makeup to your sleeping habits to your zip code can show you exactly what diseases you face, when they occur and how to prevent them; and where gene editing can make serious diseases for which there are no known cures a thing of the past.
Click here to download the full Vantage Report.
Precision medicine has the potential to change the way we think about healthcare. It shifts the emphasis from treating disease to maintaining health, and from episodic care to continuous vigilance. It turns passive patients into proactive participants in their own health care. And it replaces trial-and-error approaches based on population averages with more accurate diagnoses and targeted therapies.
But such transformative outcomes require far-reaching changes. We often hear about the impact that precision medicine will have on healthcare systems and how we personally manage our health. But what about those charged with bringing precision medicine tests and treatments to the market? What do they do, what challenges do they face, and how do they work with stakeholders within the broader healthcare ecosystem?
To learn more about industry practices, Bristol-Myers Squibb, Medidata Solutions and Thermo Fisher Scientific conducted research sponsored by Tekk.tv Vantage to survey diagnostic developers and biotechnology and pharmaceutical (biopharmaceutical) organizations involved in drug discovery and development in the U.S., U.K., Germany and France. We supplemented the survey results with in-depth interviews that offer different perspectives on the role of precision medicine in healthcare.
Click here to download the full Vantage report.